S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
Log in
NASDAQ:BMRA

Biomerica Stock Forecast, Price & News

$5.46
-0.13 (-2.33 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.27
Now: $5.46▼
$5.54
50-Day Range
$5.40
MA: $6.77▼
$7.85
52-Week Range
$2.05
Now: $5.46▼
$23.39
Volume145,106 shs
Average Volume848,271 shs
Market Capitalization$64.17 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.83
Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.93 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BMRA
Previous Symbol
CUSIPN/A
CIK73290
Webwww.biomerica.com
Phone949-645-2111
Employees65

Debt

Debt-to-Equity RatioN/A
Current Ratio7.28
Quick Ratio5.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.69 million
Price / Sales9.59
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.43 per share
Price / Book3.82

Profitability

EPS (Most Recent Fiscal Year)($0.23)
Net Income$-2,340,000.00
Net Margins-52.42%
Return on Equity-40.08%
Return on Assets-28.77%

Miscellaneous

Outstanding Shares11,753,000
Market Cap$64.17 million
Next Earnings Date1/20/2021 (Estimated)
OptionableNot Optionable
$5.46
-0.13 (-2.33 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biomerica (NASDAQ:BMRA) Frequently Asked Questions

How has Biomerica's stock been impacted by COVID-19 (Coronavirus)?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BMRA stock has increased by 88.3% and is now trading at $5.46.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Biomerica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Biomerica.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Wednesday, January 20th 2021.
View our earnings forecast for Biomerica.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) issued its quarterly earnings results on Thursday, October, 15th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. The business had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.09 million. Biomerica had a negative return on equity of 40.08% and a negative net margin of 52.42%.
View Biomerica's earnings history.

What price target have analysts set for BMRA?

1 brokerages have issued twelve-month price objectives for Biomerica's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Biomerica's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 101.5% from the stock's current price.
View analysts' price targets for Biomerica.

Are investors shorting Biomerica?

Biomerica saw a drop in short interest in September. As of September 30th, there was short interest totaling 665,300 shares, a drop of 17.5% from the September 15th total of 806,300 shares. Based on an average trading volume of 532,300 shares, the short-interest ratio is currently 1.2 days. Approximately 7.4% of the company's shares are sold short.
View Biomerica's Short Interest.

Who are some of Biomerica's key competitors?

Some companies that are related to Biomerica include VolitionRx (VNRX), Riot Blockchain (RIOT), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), OncoCyte (OCX), OncoCyte (OCX), Navidea Biopharmaceuticals (NAVB), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), ImmuCell (ICCC), Achieve Life Sciences (ACHV), StageZero Life Sciences (GNWSF), StageZero Life Sciences (GNWSD), Arca Biopharma (ABIO) and Akers Biosciences (AKER).
View all competitors.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), Opko Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

Who are Biomerica's key executives?

Biomerica's management team includes the following people:
  • Mr. Zackary S. Irani, Chairman & CEO (Age 54, Pay $136.61k)
  • Mr. Allen C. Barbieri, Exec. Vice-Chairman (Age 62, Pay $7.5k)
  • Ms. Janet Moore, Treasurer, Sec. & Director (Age 69, Pay $109.11k)
  • Mr. Steven Sloan, Chief Financial Officer (Age 50)

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Emerald Advisers LLC (0.09%). Company insiders that own Biomerica stock include Catherine Coste and Mark A Sirgo.
View institutional ownership trends for Biomerica.

Which institutional investors are buying Biomerica stock?

BMRA stock was purchased by a variety of institutional investors in the last quarter, including Emerald Advisers LLC.
View insider buying and selling activity for Biomerica.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $5.46.

How big of a company is Biomerica?

Biomerica has a market capitalization of $64.17 million and generates $6.69 million in revenue each year. The company earns $-2,340,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Biomerica employs 65 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is www.biomerica.com.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.

This page was last updated on 10/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.